Aurion Biotech
Note: Aurion Biotech withdrew its plans for an IPO in a letter to the SEC dated May 23, 2025. Alcon, Aurion’s largest shareholder, bought a majority stake in Aurion Biotech in March 2025. We are a commercial-stage biotech focused on developing regenerative cell therapies for eye diseases. We are working on advancing a single allogeneic […]
June 3, 2025 Read More